PMID: 29490099
Lifestyle interventions were the least effective treatment, the investigators found, producing a mean total body weight loss of 7.4% at the end of the treatment period, followed by a mean per-month weight regain of 0.14%, with participants reaching their pre-intervention weights within 4.1 years
FDA-Approved Options for Adolescents Some obesity medications have been approved for adolescents ages 12 to 17, but approval does not mean they should be used casually
White-Springer (Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writingreview & editing)
Plaintiffs in current and potential lawsuits allege that manufacturers failed to adequately warn about serious risks associated with Ozempic and similar medications
Stopping the medication often leads to the return of appetite and potential weight regain